CARsgen’s satricabtagene autoleucel approved for gastric cancer in China
Satricabtagene autoleucel becomes the first CAR-T cell therapy approved for solid tumors, achieving a 22% response rate in advanced...
Amylyx’s avexitide meets Phase 3 endpoints in post-bariatric hypoglycemia trial
Amylyx's avexitide meets Phase 3 endpoints in post-bariatric hypoglycemia trial, offering the first FDA-backed treatment option for a condition...
WCG Report: Site Delays and Phase II Terminations Rise in 2025 Clinical Trials
Phase II trial terminations rose to 31% in 2025, driven by site delays and participant dropout. WCG report reveals...
AbelZeta Gets FDA IND Clearance for Prizlon-cel in Large B-Cell Lymphoma
AbelZeta obtains FDA IND clearance for Prizlon-cel, a bispecific CAR-T therapy targeting CD20/CD19 in large B-cell lymphoma, backed by...
Meant Launches LegitScript-Certified GLP-1 Telehealth Platform with Coaching
Meant launches LegitScript-certified GLP-1 telehealth platform with coaching support and prescription services across all 50 states.
Skye Bioscience Acquires Redx Pharma, Exits Obesity for Fibrosis Focus
Skye Bioscience acquires Redx Pharma and exits obesity development to pivot toward fibrosis and oncology with $125M financing.
Aizen Raises Up to $100M Per Target in San Diego Biotech Peptide Deal
Aizen Therapeutics secured a multi-program collaboration worth up to $100M per target using AI-designed peptides for immunology and neurology...
Citius Pharmaceuticals Reports LYMPHIR Revenue Growth, Explores CAR-T Combination
LYMPHIR shows 86% response rate when combined with CAR-T therapy in relapsed or refractory diffuse large B-cell lymphoma patients.
Nektar Raises Cash to Fund Rezpegaldesleukin Phase 3 Trials Through 2028
Nektar raises $373.8M to fund rezpegaldesleukin Phase 3 trials through 2028, with data readouts expected mid-2028 in atopic dermatitis.
Inhibrx Reports Q2 2026 Loss, Advances Ozekibart Toward FDA Decision
Inhibrx advances ozekibart toward FDA approval in chondrosarcoma with April 2027 PDUFA date while expanding colorectal cancer trials.